Previous 10 | Next 10 |
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that is has been named one of the Top 100 Adoption-Friendly Workplaces in the United States by the Dave Thomas Foundation for Adoption for the third year in a row. The list, which recognizes organizations with the most robust a...
Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...
-- Data show notable decline in disease-related attacks after the first year of treatment in patients receiving UPLIZNA for four or more years -- -- Consistent safety profile maintained throughout long-term study period with no treatment discontinuations -- Horizon T...
-- Presentations will feature analyses from the pivotal N-MOmentum study and the role of B-cell depletion in NMOSD disease activity reduction -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new UPLIZNA and NMOSD data analyses will be presented at the virtual ...
My portfolio, built specifically for my retirement ~20+ years from now, rides the September downturn in the market back under $400k. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a valuable reti...
Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) traded today at a new 52-week high of $112.36. So far today approximately 128,000 shares have been exchanged, as compared to an average 30-day volume of 967,000 shares. Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) def...
-- Announcing Five Total New Development Programs for Daxdilimab (HZN-7734) and Dazodalibep (HZN-4920); Expect to Initiate New Phase 2 Trials in 2022, Bringing Total Development Programs to 27 -- --Positioned for Growth with Expanding R&D Team, New Disease Areas and Manufa...
Halvorsen's 13F portfolio value decreased marginally from $33.58B to $32.98B this quarter. The number of positions decreased from 94 to 88. Viking Global added FIGS Inc. & JD.com and increased Amazon.com & General Electric during the quarter. The top three positions are Am...
-- Event Begins at 9 a.m. ET -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the agenda for its virtual R&D Day for investors and analysts on Sept. 29, 2021. During the event, Horizon’s R&D leadership, executives and key opinion leaders will discuss...
-- Analysis of 20 African Americans from the pivotal study presented at the 15th World Congress on Controversies in Neurology -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced results of a retrospective analysis of the pivotal Phase 2/3 N-MOmentum clinical trial, in...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...